Alerts will be sent to your verified email
Verify EmailWANBURY
|
Wanbury
|
Lincoln Pharma
|
Syncom Formulations
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
58.3 % | 15.1 % | 9.79 % |
|
5yr average Equity Multiplier
|
-1.35 | 1.26 | 1.41 |
|
5yr Average Asset Turnover Ratio
|
1.54 | 0.82 | 0.81 |
|
5yr Avg Net Profit Margin
|
5.09 % | 14.59 % | 8.78 % |
|
Price to Book
|
20.25 | 1.59 | 3.11 |
|
P/E
|
27.92 | 13.68 | 16.88 |
|
5yr Avg Cash Conversion Cycle
|
-103.0 Days | -6.41 Days | 61.57 Days |
|
Inventory Days
|
21.96 Days | 43.91 Days | 27.32 Days |
|
Days Receivable
|
61.39 Days | 91.75 Days | 82.75 Days |
|
Days Payable
|
194.51 Days | 128.38 Days | 79.41 Days |
|
5yr Average Interest Coverage Ratio
|
2.13 | 63.13 | 31.44 |
|
5yr Avg ROCE
|
-37.9 % | 19.81 % | 13.63 % |
|
5yr Avg Operating Profit Margin
|
7.72 % | 18.35 % | 9.97 % |
|
5 yr average Debt to Equity
|
0.2 | 0.0 | 0.19 |
|
5yr CAGR Net Profit
|
n/a | 5.76 % | 36.24 % |
|
5yr Average Return on Assets
|
7.92 % | 11.92 % | 7.11 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
43.02 % | 49.78 % | 50.57 % |
|
Share Pledged by Promoters
|
62.18 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
3.18 % | 1.11 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Wanbury
|
Lincoln Pharma
|
Syncom Formulations
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|